Paragon Biosciences
Chicago-based Paragon innovates in life sciences, focusing on AI, gene therapy, synthetic biology, and biopharmaceuticals.
Founded
2010Chicago-based Paragon innovates in life sciences, focusing on AI, gene therapy, synthetic biology, and biopharmaceuticals.
Paragon Biosciences, founded in Chicago, Illinois, is a pioneering life sciences company dedicated to creating, investing in, and building bioscience enterprises. The company's core mission is to advance human health by leveraging cutting-edge technologies in artificial intelligence, gene therapy, synthetic biology, and biopharmaceuticals. Paragon's vision is to transform patient outcomes through innovative solutions that address unmet medical needs. Their market focus spans across various sectors of life sciences, aiming to develop breakthrough therapies and technologies.
Notable affiliated individuals include Jeff Aronin, a prominent figure in the biopharmaceutical industry known for his leadership and entrepreneurial expertise. Paragon has attracted significant investment from both private and institutional investors, enabling it to fund and support multiple high-impact bioscience ventures. Key achievements include the successful launch and growth of several portfolio companies that have made substantial advancements in their respective fields. Overall, Paragon Biosciences has made a profound impact on the life sciences industry by fostering innovation and accelerating the development of transformative medical solutions.
Companies similar to Paragon Biosciences include Regenerative Bio, Paratus Sciences, Paragon Genomics and Emalex Biosciences.
Paragon Biosciences was founded in 2010.
Paragon Biosciences' headquarters is located in Chicago, IL, US.
Paragon Biosciences' most recent funding round was for $185M (USD) in November 2022.
As of Nov 4, 2022, Paragon Biosciences has raised a total of $282.6M (USD).
Paragon Biosciences has 26 employees as of Feb 4, 2024.
Paragon Genomics
